7:00 AM — 6:45 PM

Exhibits Open

7:00 AM — 8:00 AM

Continental Breakfast Provided

8:00 AM — 9:45 AM

General Session I: Cancers of the Esophagus and Stomach: Prevention, Screening, and Diagnosis

(Welcome 8:00 AM — 8:15 AM)
Chairs: Paulo M. Hoff, MD, PhD — Universidade de Sao Paulo; Mark Krasna, MD — St. Joseph Medical Center

• Chemoprevention of Barrett’s and Esophageal Adenocarcinoma: State of the Art in the Year 2012
  Janusz A. Z. Jankowski, MD, MBBS - Digestive Diseases Center, QMUL
   
• Differentiating between T1A and T1B Esophageal Cancers: The Role of Endoscopic Mucosal Resection and Pathologic Interpretation
  Mary P. Bronner, MD - The Cleveland Clinic Foundation
   
• Role of PET in Staging and Treatment of Gastric and Esophageal Cancers
  Karyn A. Goodman, MD - Memorial Sloan-Kettering Cancer Center
   
• Functional Imaging Techniques in Prevention, Screening, and Diagnosis
  Lawrence H. Schwartz, MD - Columbia University Medical Center
   
• Abstract #1: Optimized response prediction in esophagogastric junction adenocarcinomas (EGJAc) with combination of molecular biomarkers and FDG-PET.
  Presenting Author: Russell D. Petty

9:45 AM — 10:15 AM

Break

10:15 AM — 11:45 AM

General Session II: Cancers of the Esophagus and Stomach: Translational Research

Chairs: Allan Pickens, MD - Emory University; Christopher Willett, MD - Duke University Medical Center

• Prognostic, Diagnostic, and Therapeutic Applications of MicroRNA Signature
  Carlo M. Croce, MD - The Ohio State University Medical Center
   
• Moving from Genomics to Therapeutics in Upper Gastrointestinal Cancers
  Wael M. El-Rifai, MD, PhD - Vanderbilt University Medical Center
   
• The Future of Targeted Therapy in Upper Gastrointestinal Cancers
  Manish Shah, MD - Memorial Sloan-Kettering Cancer Center
   
• Abstract #2: The prognostic significance of extra-intestinal tumor location for primary nonmetastatic gastrointestinal stromal tumors.
  Mary Lydon Guye, MD – City of Hope National Medical Center

11:45 AM — 1:45 PM

General Poster Session A: Cancers of the Esophagus and Stomach

(with complimentary boxed lunch)

12:00 PM — 1:00 PM

Fellows, Residents, and Junior Faculty Networking Luncheon (Ticketed)

Chair: Richard M. Goldberg, MD - The Ohio State University

Participants:

• William A. Blackstock, MD - Wake Forest University
• Charles D. Blanke, MD - University of British Columbia/British Columbia Cancer Agency
• Michael A. Choti, MD - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
• Aimery de Gramont, MD, PhD - Hospital Saint Antoine
• Lee M. Ellis, MD - University of Texas M. D. Anderson Cancer Center
• Charles S. Fuchs, MD - Dana-Farber Cancer Institute
• William M. Grady, MD - Fred Hutchinson Cancer Research Center
• Lisa A. Kachnic, MD - Boston Medical Center
• Alberto F. Sobrero, MD - San Martino Hospital
• Josep Tabernero, MD - Vall D'Hebron University Hospital
• Margaret A. Tempero, MD - University of California, San Francisco Comprehensive Cancer Center
• Jack Welch, MD, PhD - National Cancer Institute

12:30 PM — 1:30 PM

Translational Research Session: Understanding the Role of Metabolism in GI Carcinogenesis

Chi V. Dang, MD, PhD - The Johns Hopkins School of Medicine
 

1:45 PM — 3:15 PM

Oral Abstract Session: Cancers of the Esophagus and Stomach

Chairs: William M. Grady, MD – Fred Hutchinson Cancer Research Center; Richard Goldberg, MD – University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

• Abstract #LBA3: Phase III trial of everolimus in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
  Presenting Author: Eric Van Cutsem
   
• Abstract #4: Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322).
  Presenting Author: Yoon-Koo Kang
   
• Abstract #5: Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.
  Presenting Author: Manish A. Shah
  
  
• Discussion (Abstracts #3-5): Advanced Gastric Cancer
  David Ilson, MD, PhD – Memorial Sloan-Kettering Cancer Center
   
• Abstract #6: Outcome of trimodality-eligible esophagogastric cancer (EC) patients who declined surgery after preoperative chemoradiation.
  Presenting Author: Takashi Taketa
   
• Abstract #7: Sentinel lymph node mapping for T1 esophageal cancer.
  Presenting Author: Hiroya Takeuchi
   
• Discussion (Abstracts #6-7)
  Thomas W. Rice, MD – Cleveland Clinic Foundation

3:15 PM — 3:45 PM

Break

3:45 PM — 5:15 PM

General Session III: Cancers of the Esophagus and Stomach: Multidisciplinary Treatment*

Chairs: Yuko Kitagawa, MD, PhD, FACS - Keio University School of Medicine; A. Craig Lockhart, MD - Washington University School of Medicine

• Case Presentation: Management of T2/T3 N0 Squamous Cell Carcinoma
  Moderator: A. Craig Lockhart, MD - Washington University School of Medicine
   
• Individual perspectives from Radiation Oncology, Surgical Oncology, and Medical Oncology
  Radiation Oncology: Brian G. Czito, MD - Duke University Medical Center
  Surgery: Thomas W. Rice, MD - Cleveland Clinic
  Surgery: Yuko Kitagawa, MD, PhD, FACS - Keio University School of Medicine
  Medical Oncology: A. Craig Lockhart, MD - Washington University School of Medicine
   
• Multidisciplinary Panel Discussion

5:15 PM — 6:45 PM

General Poster Session A: Cancers of the Esophagus and Stomach

(with complimentary wine and cheese reception)

7:00 AM — 6:45 PM

Exhibits Open

7:00 AM — 8:00 AM

Continental Breakfast Provided

7:00 AM — 8:00 AM

Meet the Professor Sessions

(Four concurrent sessions - Ticketed)

•  Update on Nutritional Assessment and Support during Neoadjuvant Therapy for Esophageal and Gastric Cancers: Assessment of the Pros and Cons of Enteric Feeding Tubes, Permanent and Removable Stents, and Total Parenteral Nutrition
  Donald E. Low, MD, FACS - Virginia Mason Medical Center
   
• Modern-Day Role of an Interventional Radiologist in Metastatic Disease to the Liver: Hepatic-Directed Regional Therapies
  Jeff H. Geschwind, MD - The Johns Hopkins School of Medicine
   
• Cancer Survivorship Issues in Patients with Gastrointestinal Cancers
  Patricia A. Ganz, MD - University of California, Los Angeles Schools of Medicine and Public Health
   
• Clinical Trial Design Debate: Development of Biomarker-Driven Studies
  The Enrichment Strategy: Daniel J. Sargent, PhD - Mayo Clinic
  The Treat All Strategy: Marc Buyse, PhD - IDDI

8:00 AM — 9:45 AM

General Session I: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract: Prevention, Screening, and Diagnosis^

(Welcome 8:00 AM — 8:15 AM)
Chairs: Tushar Patel, MBChB - Mayo Clinic; Francoise Mornex, MD - Lyon University Hospital

• Abstract #151: Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay.
  Presenting Author: David V. Gold
   
• The Development of Cholangiocarcinoma: Epidemiology, Risk Factors, and Diagnosis
  Domenico Alvaro, MD - University of Rome La Sapienza
   
• Treatment of Hepatitis as a Preventive Approach for Hepatocellular Carcinoma (HCC)
  Norah A.Terrault, MD, MPH - University of California, San Francisco
   
• Guidelines for Screening and Diagnosis in Hepatocellular Carcinoma: Current Status of Diagnostic Imaging
  Tae Kyoung Kim, MD - Princess Margaret Hospital

9:45 AM — 10:15 AM

Break

10:15 AM — 11:45 AM

General Session II: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract: Translational Research^

Chairs: Mitchell Posner, MD, FACS - University of Chicago Medical Center; Sapna Syngal, MD, MPH - Dana Farber Cancer Institute

• Abstract #152: Malignant progression in intraductal papillary mucinous neoplasms of the pancreas: Results of 157 patients selected for radiographic surveillance.
  Presenting Author: Jennifer LaFemina
  
  
• Molecular Aspects of Intraductal Papillary Mucinous Neoplasms
  Masao Tanaka, MD - Kyushu University
   
• Molecular Signature of Prognosis and Outcomes in Hepatocellular Carcinoma
  Josep M. Llovet, MD - Mount Sinai School of Medicine
   
• Neuroendocrine Tumors: The Use of Molecular Features for Guiding Management
  Lillian L. Siu, MD - Princess Margaret Hospital

11:45 AM — 1:45 PM

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

(with complimentary boxed lunch)

12:30 PM — 1:30 PM

Translational Research Session: Cancer Stem Cell Update

Diane M. Simeone, MD - University of Michigan Health System
 

1:45 PM — 3:15 PM

Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Coleman Smith, MD – Minnesota Gastroenterology; Daniel C. Chung, MD – Massachusetts General Hospital

• Abstract #156: Neoadjuvant chemoradiation versus surgery first for resectable pancreatic head adenocarcinoma: An economic and outcome analysis.
  Presenting Author: Daniel E. Abbott
   
• Abstract #LBA154^: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
  Presenting Author: Riccardo Lencioni
   
• Discussion
  Jennifer J. Knox, MD - Princess Margaret Hospital
   
• Abstract #157: Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
  Presenting Author: James C. Yao
   
• Discussion
  Timothy J. Hobday, MD - Mayo Clinic
   
• Abstract # 158: SBRT as an alternative to RFA for the treatment of primary and metastatic liver tumors.
  Presenting Author: Erqi Liu

3:15 PM — 3:45 PM

Break

3:45 PM — 5:15 PM

General Session III: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract: Multidisciplinary Treatment*

Chairs: Gauri R. Varadhachary, MD, MBBS - University of Texas M.D. Anderson Cancer Center; Nipun B. Merchant, MD - Vanderbilt Ingram Cancer Center

• Abstract #153: The impact of vascular reconstruction on early postoperative outcomes after pancreaticoduodenectomy: An analysis of the American College of Surgeons National Surgical Quality Improvement Program database.
  Presenting Author: Anthony W. Castleberry
   
• Case Presentations and Panel Discussion: Borderline Resectable and Metastatic Pancreatic Carcinoma
  
  
• Multidisciplinary Panel
  Surgeon: Douglas B. Evans, MD - The Medical College of Wisconsin
  Medical Oncologist: Jordan Berlin, MD - Vanderbilt Ingram Cancer Center
  Radiation Oncologist: Edgar Ben-Josef, MD - University of Michigan

5:15 PM — 6:45 PM

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

(with complimentary wine and cheese reception)
 

5:45 PM — 6:45 PM

Meet the Professor Sessions

(Five concurrent sessions - Ticketed)

• Update on Nutritional Assessment and Support during Neoadjuvant Therapy for Esophageal and Gastric Cancer: Assessment of the Pros and Cons of Enteric Feeding Tubes, Permanent and Removable Stents, and Total Parenteral Nutrition
  Donald E. Low, MD, FACS - Virginia Mason Medical Center
   
• Modern-Day Role of an Interventional Radiologist in Metastatic Disease to the Liver: Hepatic-Directed Regional Therapies
  Jeff H. Geschwind, MD - The Johns Hopkins School of Medicine
   
• Novel Therapies for Palliative Care of Pancreatic Cancer
  Joo Ha Hwang, MD, PhD - University of Washington
   
• Stereotactic Radiotherapy for Hepatocellular Carcinoma and Liver Metastases
  Laura A. Dawson, MD - Princess Margaret Hospital
   
•  Clinical Trial Design Debate: Development of Biomarker-Driven Studies
  The Enrichment Strategy: Daniel J. Sargent, PhD - Mayo Clinic
  The Treat All Strategy: Marc Buyse, PhD - IDDI

7:00 AM — 8:00 AM

General Poster Session C: Cancers of the Colon and Rectum

(with complimentary continental breakfast)

8:00 AM — 8:15 AM

Welcome

8:15 AM — 9:00 AM

Keynote Lecture: On Being a Surgical Oncologist

Murray F. Brennan, MD - Memorial Sloan-Kettering Cancer Center
 

9:00 AM — 10:30 AM

General Session I: Cancers of the Colon and Rectum: Prevention, Screening, and Diagnosis^

Chairs: Frank Sinicrope, MD - Mayo Clinic; Nadir Arber, MD, MSc, MHA - Tel Aviv Sourasky Medical Center

• Prospective Cohort Studies and Colorectal Cancer: Insights into Etiology and Prevention
  Andrew T. Chan, MD - Massachusetts General Hospital and Harvard Medical School
   
• Strategies for Colorectal Cancer Prevention
  Frank L. Meyskens, Jr., MD - Chao Family Comprehensive Cancer Center
   
• DNA Methylation: Biology and Potential Screening Strategies
  Peter W. Laird, PhD - University of Southern California Norris Comprehensive Cancer Center
   
• Stool DNA Testing: A Step Closer to Eradicating Colorectal Cancer
  David A. Ahlquist, MD - Mayo Clinic

10:30 AM — 11:00 AM

Break

11:00 AM — 12:30 PM

General Session II: Cancers of the Colon and Rectum: Translational Research^

Chairs: George A. Fisher, MD, PhD - Stanford Cancer Center; Wells Messersmith, MD - University of Colorado Cancer Center

• The Role of Targeted Therapy in Adjuvant Colon Cancer Trials: Where Did We Go Wrong, and Where Do We Go from Here?
  Alberto F. Sobrero, MD - San Martino Hospital
   
• Molecular Insights from the Pan-European Trials in Adjuvant Colon Cancer
  Sabine Tejpar, MD, PhD - University Hospital Gasthuisberg
   
• Targeting KRAS for the Treatment of Gastrointestinal Cancers: Mission Impossible?
  Channing J. Der, PhD - University of North Carolina Lineberger Comprehensive Cancer Center
   
• Vision of Molecular Targeted Therapies in Colorectal Cancer in 2012
  James H. Doroshow, MD - National Cancer Institute
   
• Abstract #383: Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
  Presenting Author: Marc Peeters

12:30 PM — 2:30 PM

General Poster Session C: Cancers of the Colon and Rectum

(with complimentary boxed lunch)

1:15 PM — 2:15 PM

Translational Research Session: Biology and Potential Therapeutic Implications of Autophagy

Robin Mathew, PhD - The Cancer Institute of New Jersey
 

2:30 PM — 4:00 PM

Oral Abstract Session: Cancers of the Colon and Rectum

Cornelis J.H. van de Velde, MD, PhD – Leiden University Medical Center; Lisa A. Kachnic, MD – Boston Medical Center

• Abstract #LBA385: Results of a phase III randomized, double-blind, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
  Presenting Author: Axel Grothey
   
• Abstract #386: Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.
  Presenting Author: Lillian L. Siu
  
  
• Abstract #387: Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).
  Presenting Author: Alberto F. Sobrero
   
• Discussion
  Herbert Hurwitz, MD – Duke University Medical Center
   
• Abstract #388: Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).
  Presenting Author: Hans-Joachim Schmoll
   
• Abstract #389: Clinical results at 3 years of the ACCORD 12 randomized trial in rectal cancer.
  Presenting Author: Jean-Pierre Gerard
   
• Discussion
  S. Gail Eckhardt, MD - University of Colorado School of Medicine

4:00 PM — 4:30 PM

Break

4:30 PM — 6:00 PM

General Session III: Cancers of the Colon and Rectum: Multidisciplinary Treatment*

Chairs: James C. Cusack Jr., MD - Massachusetts General Hospital; Steven Curley, MD - University of Texas M.D. Anderson Cancer Center

• Debate over Molecular Profiling for Stage II Colon Cancer Patients
  
  Pros: Use in Adjuvant Treatment Decisions in Stage II Colon Cancer
  George J. Chang, MD, MS- University of Texas M.D. Anderson Cancer Center
  
  Cons: Practicality and Clinical Implications
  Neal J. Meropol, MD - Case Western Reserve University
   
• A Global Approach to Borderline Resectable/Unresectable Colorectal Liver Metastases
  Surgical Oncologist: Michael A. Choti, MD, MBA - The Sidney Kimmel Comprehensive Cancer Center at Johns
  Medical Oncologist: David Cunningham, MD, FRCP - The Royal Marsden Hospital
   
• Abstract #384: Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer.
  Presenting Author: Josep Tabernero

— Indicates Ticketed Session (information on registering for ticketed sessions)
Sessions with an asterisk (*) indicate use of the Audience Response System (ARS)
Sessions with a carat (^) indicate use of the electronic Q&A system (e-Q&A)